Glycopyrronium Biogaran (Glycopyrronium Bromide)

Glycopyrronium Biogaran is indicated for the long‑term treatment of chronic obstructive pulmonary disease (COPD) and for relief of bronchospasm associated with COPD. It is administered by inhalation as part of a maintenance therapy regimen.

• Maintenance bronchodilator therapy in patients with moderate to severe COPD.
• Prevention of COPD‑related bronchospasm episodes.
• Use as a single‑agent inhaled anticholinergic when a long‑acting muscarinic antagonist is required.
• Adjunct to other COPD medications such as inhaled corticosteroids or long‑acting β2‑agonists, as directed by a clinician.
• Suitable for patients who require a once‑daily inhaled anticholinergic agent.

The safety profile of inhaled glycopyrronium bromide reflects its anticholinergic activity in the respiratory tract.

Common

• Dry mouth or altered taste sensation.
• Cough, throat irritation, or hoarseness after inhalation.
• Upper respiratory tract infection‑like symptoms.
• Urinary hesitancy or difficulty emptying the bladder.

Serious

• Paradoxical bronchospasm requiring immediate medical attention.
• Severe allergic reaction, including rash, swelling, or anaphylaxis.
• Rapid heart rate (tachycardia) or palpitations.

Clinicians should evaluate individual risk factors before prescribing Glycopyrronium Biogaran and advise patients on appropriate use.

• Assess for history of narrow‑angle glaucoma or urinary retention before initiating therapy.
• Use caution in patients with cardiovascular disease, especially tachyarrhythmias.
• Monitor for signs of paradoxical bronchospasm after the first doses.
• Advise patients to rinse the mouth after inhalation to reduce oral side effects.
• Not recommended for use during acute COPD exacerbations without medical supervision.
• Consider renal or hepatic impairment may affect drug exposure; dose adjustment may be needed.
• Pregnancy and lactation status are not well established; use only if benefit outweighs risk.

Glycopyrronium bromide may interact with other medications that affect cholinergic pathways or cardiac conduction.

Avoid

• Concurrent use with other anticholinergic agents (e.g., ipratropium) that may increase anticholinergic burden.
• Beta‑agonist bronchodilators that can cause additive cardiovascular effects when combined with high doses.
• Strong CYP3A4 inhibitors if systemic exposure is significant (though inhaled exposure is low).

Use with caution

• Beta‑blockers, especially non‑selective agents, which may blunt bronchodilator response.
• Drugs that prolong QT interval, as additive cardiac effects are possible.
• Antihistamines or tricyclic antidepressants that have anticholinergic properties.
• Diuretics, because of potential for urinary retention.